These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 21412389)

  • 81. Combination antiretroviral therapy toxicities: a comparison between patients and health care professionals.
    Nelson M; Yau S; Baber L; Myers J; Ward B; Sonecha S; Bower M; Gazzard B; Stebbing J
    J Acquir Immune Defic Syndr; 2011 Apr; 56(4):e120-1. PubMed ID: 21350362
    [No Abstract]   [Full Text] [Related]  

  • 82. Cardiovascular complications in HIV management: past, present, and future.
    Aberg JA
    J Acquir Immune Defic Syndr; 2009 Jan; 50(1):54-64. PubMed ID: 19295335
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Dietary intake and dyslipidemia arising from combination antiretroviral therapy for HIV infection: a systematic review].
    Almeida LB; Giudici KV; Jaime PC
    Arq Bras Endocrinol Metabol; 2009 Jul; 53(5):519-27. PubMed ID: 19768243
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Drug interactions during periodontal therapy in HIV-infected subjects.
    Gonçalves LS; Gonçalves BM; de Andrade MA; Alves FR; Junior AS
    Mini Rev Med Chem; 2010 Jul; 10(8):766-72. PubMed ID: 20565386
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy.
    Li SX; Armstrong A; Neff CP; Shaffer M; Lozupone CA; Palmer BE
    Clin Pharmacol Ther; 2016 Jun; 99(6):600-11. PubMed ID: 26940481
    [TBL] [Abstract][Full Text] [Related]  

  • 86. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era.
    Ballocca F; Gili S; D'Ascenzo F; Marra WG; Cannillo M; Calcagno A; Bonora S; Flammer A; Coppola J; Moretti C; Gaita F
    Prog Cardiovasc Dis; 2016; 58(5):565-76. PubMed ID: 26943980
    [TBL] [Abstract][Full Text] [Related]  

  • 87. HIV-related cardiovascular disease and drug interactions.
    Nanavati KA; Fisher SD; Miller TL; Lipshultz SE
    Am J Cardiovasc Drugs; 2004; 4(5):315-24. PubMed ID: 15449973
    [TBL] [Abstract][Full Text] [Related]  

  • 88. HIV and its relationship to insulin resistance and lipid abnormalities.
    Non LR; Escota GV; Powderly WG
    Transl Res; 2017 May; 183():41-56. PubMed ID: 28068521
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Left ventricular dysfunction in human immunodeficiency virus infection.
    Cade WT
    J Cardiometab Syndr; 2008; 3(2):83-7. PubMed ID: 18453807
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Management of dyslipidemia in HIV-infected patients].
    Moog AM; Becker W
    MMW Fortschr Med; 2012 May; 154 Suppl 1():34-6. PubMed ID: 22916597
    [No Abstract]   [Full Text] [Related]  

  • 91. HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.
    Zou W; Berglund L
    Prev Cardiol; 2007; 10(2):96-103; quiz 104-5. PubMed ID: 17392622
    [No Abstract]   [Full Text] [Related]  

  • 92. Gynaecomastia in HIV-infected men: association with effects of antiretroviral therapy.
    Paech V; Lorenzen T; von Krosigk A; Graefe K; Stoehr A; Plettenberg A
    AIDS; 2002 May; 16(8):1193-5. PubMed ID: 12004284
    [No Abstract]   [Full Text] [Related]  

  • 93. [Antiretrovirus drugs impair kidneys in HIV-infection].
    Iushchuk ND; Volgina GV; Tomilina NA; Gadzhikulieva MM
    Ter Arkh; 2011; 83(11):66-70. PubMed ID: 22312890
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?
    Kumarasamy N; Patel A; Pujari S
    Indian J Med Res; 2011 Dec; 134(6):787-800. PubMed ID: 22310814
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Antiretroviral-associated liver injury.
    Ogedegbe AO; Sulkowski MS
    Clin Liver Dis; 2003 May; 7(2):475-99. PubMed ID: 12879995
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism.
    de Almeida ER; Reiche EM; Kallaur AP; Flauzino T; Watanabe MA
    Biomed Res Int; 2013; 2013():836790. PubMed ID: 24319689
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dyslipidemia in HIV patients.
    Tungsiripat M; Aberg JA
    Cleve Clin J Med; 2005 Dec; 72(12):1113-20. PubMed ID: 16392725
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy.
    Corrales-Medina VF; Simkins J; Chirinos JA; Serpa JA; Horstman LL; Jy W; Ahn YS
    J Acquir Immune Defic Syndr; 2010 Jun; 54(2):217-8. PubMed ID: 20505474
    [No Abstract]   [Full Text] [Related]  

  • 99. Tolerance of highly active antiretroviral therapy in HIV patients: a 3-year follow up.
    Beltrame A; Del Bono V; Marturano M; Pedemonte P; Rosso R; Mazzarello G; Bassetti M; Collidà A; Fusco F; Bassetti D
    Int J Antimicrob Agents; 2000 Nov; 16(3):361-2. PubMed ID: 11091064
    [No Abstract]   [Full Text] [Related]  

  • 100. Ischemic Heart Disease in HIV: An In-depth Look at Cardiovascular Risk.
    Raposeiras-Roubín S; Triant V
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1204-1213. PubMed ID: 27840147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.